Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 169

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 8
Chunk 169
---
,293 336 (563)858,066 Non-current:U.S. Treasuries119,706 579 (8)120,277 Government securities94,964 28 (132)94,860 Corporate debt securities184,915 450 (35)185,330 Total non-current399,585 1,057 (175)400,467 Total marketable securities$1,257,878 $1,393 $(738)$1,258,533 Marketable securities at December 31, 2024 consisted of the following:(In thousands)AmortizedCostUnrealizedGainsUnrealizedLossesFairValueCurrent:Certificates of deposit$10,374 $11 $— $10,385 U.S. Treasuries173,465 153 (27)173,591 Government securities167,970 103 (75)167,998 Corporate debt securities465,427 321 (259)465,489 Total current817,236 588 (361)817,463 Non-current:U.S. Treasuries107,725 106 (303)107,528 Government securities112,175 3 (469)111,709 Corporate debt securities420,166 181 (1,263)419,084 Total non-current640,066 290 (2,035)638,321 Total marketable securities$1,457,302 $878 $(2,396)$1,455,784 As of June 30, 2025 and December 31, 2024, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i) have a maturity of greater 

9

than one year, and (ii) we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.As of June 30, 2025 and December 31, 2024, we held 123 and 213 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of June 30, 2025 and December 31, 2024 related to these securities. The aggregate fair value of debt securities in an